Evaluation of the clinical benefits of One Touch VerioIQ system.
Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains pattern alert technology and comes with educational material (Pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
BGM with pattern alert technology and with associated pattern guide
Change in A1C from baseline to week 24
A1C (also known as hemoglobin A1C or glycosylated hemoglobin)
Time frame: 24 weeks
Change in A1C from baseline to week 12
Time frame: 12 weeks
Change in FPG from baseline to 24 weeks
FPG (Fasting plasma glucose)
Time frame: 24 weeks
Change in proportion of subjects with A1C less than or equal to 7.0% at week 24
Time frame: 24 weeks
Change in 30 day mean glucose comparing first month to last month after 24 weeks
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.